the TAMI Study Group
To evaluate the clinical incidence and outcomes of patients with pericarditis after thrombolytic therapy, 810 patients were prospectively studied during acute myocardial infarction (AMI). Pericarditis was defined as the presence of a pericardial friction rub during the hospital course. Only 5% of patients developed a rub during AMI, a low percent compared with that in the prethrombolytic era. A pericardial friction rub more often occurred in the setting of an anterior wall AMI. Patients wlth, compared to those without, a pericardial friction rub had lower ejection fractions (45 vs 51%, p = 0.002); worse regional left ventricular function (-3.2 vs 2.7, standard deviatlon per chord); higher in-hospital mortality (15 vs 6%, p = 0.056); a higher frequency of power failure (83 vs 57%); a higher frequency of anterior wall location of the AMI (53% of cases, p = 0.002); and a higher frequency of 3-vessel disease. Therefore, although the frequency of a pericardial friction rub was low (5%) compared with that in the prethrombolytic era, its occurrence denotes more extensive myocardial damage with a worse clinical outcome. Perhaps with successful reperfusion of the infarct-related vessel, transmural myocardial necrosis is prevented and with it the development of pericarditis. Cardiac tamponade did not occur clinically in any patient who developed 'a pericardial friction rub. B efore the era of thrombolytic therapy, pericarditis in acute myocardial infarction (AMI) was reported to occur in approximately 7 to 20% of patients.1-6 Based on clinical and pathologic studies, the presence of extensive transmural necrosis was believed to be a prerequisite for the development of pericardial inflammation.7 Hospital and long-term mortality has been reported to be higher in conservatively treated patients with evidence of pericarditis after AMI.3-5 By achieving early reperfusion, the use of thrombolytic therapy may prevent progression to transmural necrosis, thereby reducing the risk of developing pericarditis. 8 Once an inflammatory reaction has developed, the risk of the development of hemorrhagic pericardial tamponade may be increased. 9 Although pericarditis has been previously reported to occur less frequently in patients given thrombolytic therapy in the setting of AMI,l"-12 the frequency and clinical outcomes of pericarditis after this treatment has not been systematically studied. This study reports, the cumulative Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) study's experience with pericarditis in the setting of thrombolytic intervention.
METHODS
Patients: Patients with AM1 complicated by pericarditis were identified in the TAM1 trials 1 through 3 and in the Urokinase Pilot Study at Duke University Medical Center. Pericarditis was strictly defined as the presence of a pericardial friction rub on auscultation on physical examination at any time during the patient's hospitalization. The patients were examined at least daily by the attending physician and study nurses.
As previously described, patients with AM1 were prospectively enrolled in trials of intravenous thrombolytic therapy if they met the standard treatment criteria.13-16 Briefly, inclusion criteria included: (1) symptoms consistent with an AM1 for 30 minutes' duration without response to sublingual nitroglycerin, (2) STsegment elevation of > 1 mm in 2 2 contiguous electrocardiographic leads, (3) onset of chest discomfort within 6 hours of the time of thrombolytic therapy administration, and (4) age <76 years. Usual exclusion criteria included: (1) no bleeding diathesis, (2) absence of cardiogenic shock, and (3) no prior coronary artery bypass surgery. ThePapsutCc regimens: The 4 thrombolytic therapy trials with their respective pharmacologic intervemions are displayed in Table I .13-i6 As previously reported, after immediate catheterization, all patients were treated with standard therapy including lidocaine, oxygen, morphine as needed for pain and nitrates either topically or intravenously. Aspirin, 325 mg/day, was also administered along with a continuous infusion of intravenous heparin to maintain the partial thromboplastin time at 2 times the control value. This infusion was continued until repeat catheterization at 7 to 10 days. Beta blockers were not added to the medical regimen unless clinically indicated for systemic hypertension, supraventricular tachyarrhythmias or noncardiac disorders (e.g., migraine headaches). Patients were also treated with calcium antagonists 3 times a day. Other medications, including antiarrhythmic agents, were used at the discretion of the clinician. No other antiplatelet agents such as dipyridamole were used routinely. ata analysis: Case report forms were completed by the clinical research nurse coordinators and reviewed by the principal investigator at each site before submission to the Duke Data Coordinating Center. The data were verilied independently by study monitors from review of the clinical records.
Throughout the clinical trials reviewed in this report, a consistent database was maintained to allow for assurance about variable definition and recording of events. Values for continuous variables are presented as mean t-1 standard deviation (SD) and for discrete variables values are presented as percentages. For discrete variables, comparisons were made by the chi-square test or the Fisher's exact test and by t tests for continuous variables. All p values presented are Zsided.
The frequencies of pericardial friction rub for the different studies are listed in Table II examined, 40 (4.9%) had evidence of clinical pericarditis during the hospitalization. The variability among the different phases of the thrombolytic studies was not substantial.
Baseline characteristics for patients with or without a pericardial rub did not differ with regard to gender, demographics and standard cardiac risk factors (Table  III) . Of the 40 cases, 23 (58%) had a rub detected within 48 hours of initial presentation.
Patients with anterior wall AMI had a higher incidence of a pericardial friction rub than those with inferior AM1 (Table IV) . Similarly, the left anterior descending coronary artery was more often the infarctrelated artery in the pericarditis group. Patients who developed a friction rub had more severe coronary dis-ease than those who did not (33% with 3-vessel or left main disease versus 17%). No difference was apparent in acute catheterization Thrombolysis in Myocardial Infarction study flow grades between those with or without clinical pericarditis.
Patients with clinical pericarditis had a significantly lower global ejection fraction at the time of acute ventriculography (Figure 1 ): Median global ejection fraction was 45% for those with and 51% for those without (p = 0.002). Infarct zone function measured in SDS per chord was significantly worse at the time of catheterization in patients who developed clinical pericarditis (Figure 2) . Median infarct zone function (SD per chord) was -3.2 in patients with a pericardial rub compared with -2.7 SD per chord in patients without a pericardial rub (p = 0.024). Of these 2 measurements, global left ventricular ejection fraction at baseline catheterization was the most important parameter for predicting the presence or absence of a pericardial friction rub (p = 0.01). This finding was independent of infarction location.
When clinical outcomes were examined, patients who developed a friction rub tended to do worse than those who did not (Table V) . Hospital mortality was higher in patients with (15%) compared with those without clinical pericarditis (6%) (p = 0.056). In patients with a rub who died, power failure tended to be the predominant mechanism (83%), whereas in patients without a rub, the cause of death was more evenly distributed between power failure (57%) and other factors, mostly arrhythmia. No patient in either group developed a hemodynamically significant pericardial effusion or cardiac tamponade by bedside clinical evaluation. This negative finding has an upper 95% confidence limit of approximately 0.4%.
DISCUSSION
The principal finding of this study is that the incidence of a pericardial friction rub in the setting of thrombolytic therapy for AM1 is especially low compared with older studies describing conservatively treated patients.5 A pericardial friction rub was only found in 5% of all patients. In contrast, the incidence of pericarditis before the thrombolytic era has been reported to be between 7 and 20%. In the recently reported Multicenter Investigation of the Limitation of Infarct Size study, in which patients did not receive thrombolytic therapy, pericarditis occurred in 20% of those enrolled. The patients in this study who developed clinical pericarditis had more extensive myocardial damage, as documented by significantly worse baseline global and segmental left ventricular function, more frequent occurrence of anterior wall AMI, and a higher in-hospital mortality as opposed to those without pericarditis. In fact, the degree of left ventricular damage as measured by global ejection fraction predicted the presence of a friction rub indeDendentlv on infarct location. These findings are cons&tent w&h those reported before the thrombolytic era and with the pathologic findings suggesting that transmural extension of myocardial necrosis is a prerequisite for the development of a pericardial friction rub. As recently reported by Sugiura et all7 patients who develop pericarditis during AM1 have a higher pulmonary artery wedge pressure, more advanced degrees of ventricular segmental asynergy and more often have a ventricular aneurysm. Perhaps with successful reperfusion, transmural myocardial necrosis is prevented and with it develonment of clinical Dericarditis. This observation concurs with early canine pathologic studies by Reimer et al I8 describing the wave front model of myocardial necrosis.
The low incidence of a pericardial friction rub in our study concurs with the previous thrombolytic trials for AMI. In the European Cooperative Study, pericarditis occurred in 6.3% of patients treated with recombinant tissue-type plasminogen activator as opposed to 11% of patients treated with placebo. In the Netherlands and the Italian Group for the Study of Streptokinase in Mvocardial Infarction studies evaluating intravenous streptokinase versus placebo, clinical piricarditis occurred twice as frequently in patients not treated with thrombolytic therapy for AMI.10-12 These findings further support the concept that reperfusion of the infarctrelated vessel decreases the likelihood of transmural extension of the infarct and hence the occurrence of a pericardial rub.
The fact that no patient with clinical pericarditis in this study developed clinical evidence of cardiac tam-THE AMERICAN JOURNAL OF CARDIOLOGY DECEMBER 15, 1990 842 ponade is of particular importance. This finding is even more remarkable when one considers the fact that these patients were aggressively treated with concomitant anticoagulant and antiplatelet therapy. It is certainly reassuring to know that hemopericardium with tamponade is extremely unusual in this setting despite case reports to the contrary with only heparin.4J,9J9 We do not believe that the development of a pericardial friction rub in this setting is a contraindication for continuation of intravenous heparin.
